0
Il n'y a pas de produit dans le panier !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > IGF-I

IGF-I

Brief Information

Name:Insulin-like growth factor I
Target Synonym:IGF-I,Insulin-Like Growth Factor IB,Insulin-Like Growth Factor I,Somatomedin C,IGFI,IGF1A,IGF,IBP1,MGF,Mechan* growth factor,IGF1,Insulin Like Growth Factor 1,Insulin-Like Growth Factor 1 (Somatomedin C),Somatomedin-C
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:3
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

IG1-H82Q6-Cell-based assay
 IGF-I CELL

Biotinylated Human IGF-I Protein, His,Avitag™ (SPR verified) (Cat.No. IG1-H82Q6) stimulates the proliferation of Human IGF-1 R (Luc) HEK293 Reporter Cell. The EC50 for this effect is 0.1746 µg/mL. (Routinely tested)

IG1-H5245-Cell-based assay
 IGF-I CELL

Human IGF-I Protein, His Tag (Cat. No. IG1-H5245) stimulates Human IGF-1 R (Luc) HEK293 Reporter Cell. The EC50 of the effect is 0.104 µg/mL (Routinely tested).

IG1-H82Q6-SPR
 IGF-I SPR

Human IGF-I R, His Tag (Cat. No. IGR-H5229) immobilized on CM5 Chip can bind Biotinylated Human IGF-I, His,Avitag (Cat. No. IG1-H82Q6) with an affinity constant of 68 nM as determined in a SPR assay (Biacore 8K) (QC tested).

IG1-H5245-SPR
 IGF-I SPR

Biotinylated Human IGF-I R, His,Avitag (Cat. No. IGR-H82E3) immobilized on CM5 Chip can bind Human IGF-I Protein, His Tag (Cat. No. IG1-H5245) with an affinity constant of 33.9 nM as determined in a SPR assay (Biacore 8K) (QC tested).

Synonym Name

IGF-I,IGF1A,somatomedin C,MGF

Background

Insulin-like growth factor 1 (IGF-1) is also known as somatomedin C, IGF1A, IGFI, sulfation factor, and is a hormone similar in molecular structure to insulin. It plays an important role in childhood growth and continues to have anabolic effects in adults. A synthetic analog of IGF-1, mecasermin is used for the treatment of growth failure. IGF-1 consists of 70 amino acids in a single chain with three intramolecular disulfide bridges. IGF-1 has a molecular weight of 7649 daltons. IGF-1 is produced primarily by the liver as an endocrine hormone as well as in target tissues in a paracrine/autocrine fashion. IGF-1 binds to at least two cell surface receptors: the Insulin-like growth factor 1 receptor, abbreviated as "IGF1R", and the insulin receptor. The IGF-1 receptor seems to be the "physiologic" receptor - it binds IGF-1 at significantly higher affinity than the IGF-1 that is bound to the insulin receptor. Like the insulin receptor, the IGF-1 receptor is a receptor tyrosine kinase - meaning it signals by causing the addition of a phosphate molecule on particular tyrosines. Its primary action is mediated by binding to its specific receptor IGF1R, present on many cell types in many tissues. Binding to the IGF1R, a receptor tyrosine kinase, initiates intracellular signaling; IGF-1 is one of the most potent natural activators of the AKT signaling pathway, a stimulator of cell growth and proliferation, and a potent inhibitor of programmed cell death. Insulin-like growth factor 1 has been shown to bind and interact with all the IGF-1 Binding Proteins (IGFBPs), of which there are six (IGFBP1-6). Specific references are provided for interactions with IGFBP3, IGFBP4 and IGFBP7.

Clinical and Translational Updates

Related Molecule

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
ACT-01 ACT-01; OCS-05; BN-201; G-79 Phase 2 Clinical Promius Pharma Keratosis, Actinic; Optic Neuritis; Demyelinating Diseases Details
Xentuzumab BI-836845 Phase 2 Clinical C.H. Boehringer Sohn Ag & Co. Kg Neoplasms; Prostatic Neoplasms, Castration-Resistant; Breast Neoplasms; Prostatic Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Dusigitumab MEDI-573 Phase 2 Clinical Medimmune Llc Solid tumours; Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular Details
ACT-01 ACT-01; OCS-05; BN-201; G-79 Phase 2 Clinical Promius Pharma Keratosis, Actinic; Optic Neuritis; Demyelinating Diseases Details
Xentuzumab BI-836845 Phase 2 Clinical C.H. Boehringer Sohn Ag & Co. Kg Neoplasms; Prostatic Neoplasms, Castration-Resistant; Breast Neoplasms; Prostatic Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Dusigitumab MEDI-573 Phase 2 Clinical Medimmune Llc Solid tumours; Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular Details

This web search service is supported by Google Inc.

totop

Laisser un message